BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20660990)

  • 1. Hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in senescence-accelerated mice.
    Niimi K; Takahashi E; Itakura C
    Exp Anim; 2010; 59(4):441-7. PubMed ID: 20660990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex.
    González-Maeso J; Yuen T; Ebersole BJ; Wurmbach E; Lira A; Zhou M; Weisstaub N; Hen R; Gingrich JA; Sealfon SC
    J Neurosci; 2003 Oct; 23(26):8836-43. PubMed ID: 14523084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.
    Canal CE; Olaghere da Silva UB; Gresch PJ; Watt EE; Sanders-Bush E; Airey DC
    Psychopharmacology (Berl); 2010 Apr; 209(2):163-74. PubMed ID: 20165943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.
    Schindler EA; Harvey JA; Aloyo VJ
    Brain Res; 2013 Jan; 1491():98-108. PubMed ID: 23123701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of modified SHIRPA and pharmacological approach uncovers neuronal alteration in senescence-accelerated mouse prone 6 (SAMP6) strain.
    Niimi K; Takahashi E
    Neurosci Lett; 2009 Jul; 458(2):53-6. PubMed ID: 19393718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane.
    Garcia EE; Smith RL; Sanders-Bush E
    Neuropharmacology; 2007 Jun; 52(8):1671-7. PubMed ID: 17493641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.
    Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL
    Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT(2A) receptor agonist DOI.
    Santini MA; Balu DT; Puhl MD; Hill-Smith TE; Berg AR; Lucki I; Mikkelsen JD; Coyle JT
    Behav Brain Res; 2014 Feb; 259():242-6. PubMed ID: 24269270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.
    Karaki S; Becamel C; Murat S; Mannoury la Cour C; Millan MJ; Prézeau L; Bockaert J; Marin P; Vandermoere F
    Mol Cell Proteomics; 2014 May; 13(5):1273-85. PubMed ID: 24637012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
    de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
    ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G
    Liu X; Zhu H; Gao H; Tian X; Tan B; Su R
    Biochem Biophys Res Commun; 2022 Apr; 598():20-25. PubMed ID: 35149433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related difference in nociceptive behavior between SAMP6 and SAMR1 strains.
    Niimi K; Takahashi E; Itakura C
    Neurosci Lett; 2008 Oct; 444(1):60-3. PubMed ID: 18703115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice.
    Hazama K; Hayata-Takano A; Uetsuki K; Kasai A; Encho N; Shintani N; Nagayasu K; Hashimoto R; Reglodi D; Miyakawa T; Nakazawa T; Baba A; Hashimoto H
    PLoS One; 2014; 9(2):e89153. PubMed ID: 24586556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo.
    Schmid CL; Raehal KM; Bohn LM
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):1079-84. PubMed ID: 18195357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
    Smith DA; Bailey JM; Williams D; Fantegrossi WE
    J Pharmacol Exp Ther; 2014 Dec; 351(3):485-91. PubMed ID: 25271256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes inhibits the DOI-induced head-twitch response in mice.
    Miyata S; Hirano S; Kamei J
    Psychopharmacology (Berl); 2004 Dec; 177(1-2):224-9. PubMed ID: 15290007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age dependence of motor activity and sensitivity to dopamine receptor 1 agonist, SKF82958, of inbred AKR/J, BALB/c, C57BL/6J, SAMR1, and SAMP6 strains.
    Niimi K; Takahashi E; Itakura C
    Brain Res; 2009 Jan; 1250():175-82. PubMed ID: 19007759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
    Moreno JL; Holloway T; Albizu L; Sealfon SC; González-Maeso J
    Neurosci Lett; 2011 Apr; 493(3):76-9. PubMed ID: 21276828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
    Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.